

GENERAL MEETING OF MAY 3, 2022

WRITTEN QUESTIONS

Written questions may be submitted to the Company, pursuant to the rules established by law, with respect to any General Meeting. In conformity with the legislation in force, an answer is deemed to have been given to a written question provided it has been displayed on the Company's website.

On April 26, 2022 the Board received two questions from Initiative Pour un Actionnariat Citoyen association (IPAC):

1st question:

« How do you explain the fact that a large part of the global population still has no access to vaccination against COVID-19? »

Response to the written question:

« Thanks to the mobilization of all Public Health partners, the worldwide population has access to Covid 19 vaccination notably for low and middle income countries through the Covax Facility and donations made directly by countries. The manufacturers of licensed Covid 19 vaccines have demonstrated their ability to produce very large quantities of Covid 19 vaccines, and we are now in a situation where vaccine supply by far exceeds demand (<https://www.ifpma.org/resource-centre/covid-19-vaccines-and-treatments-output-continues-apace-as-health-systems-and-last-mile-hurdles-remain-collective-stumbling-blocks/>), with unfortunate consequences, including decisions to stop manufacture or even potentially destroy large numbers of doses (With 200M unused doses, AstraZeneca's COVID vaccine partner Serum Institute halts production | Fierce Pharma).

The current urgency to reach the WHO's coverage target of 70%, is to convert the vaccines that have been manufactured into vaccinations. The global health community and Governments is mobilized to bring about the necessary support to achieve delivery of vaccines into the arms of people who are not yet protected (The Break COVID Now Summit - gavi.org). A strong health system infrastructure is a fundamental component not only for this acute phase but for building robust future pandemic preparedness. »

2nd question:

« When the Company's vaccine is ready, what do you intend to do to overcome this shortcoming? »

Response to the written question:

« When our vaccine is licensed, our approach will be to first deliver on our commitments to our partners in the development of this vaccine. We will supply booster doses per our APAs with the EU, US, UK and Canada, and continue our engagement with COVAX. We will then propose our vaccine to all countries interested. »